Article Figures & Data
Tables
Ligand compared with C-11 PiB Subjects Correlation of binding between ligands Diagnostic performance Florbetapir [55] 12 AD patients, 14 cognitively normal control subjects Composite cortical binding correlation r = 0.78, P < .001 Group discrimination florbetapir area under the curve = 0.90 vs PiB = 1.0. Florbetapir [56] 24 MCI subjects, 8 healthy control subjects Composite cortical binding correlation ρ = 0.95, P < .001, slope = 0.60 97% classification agreement using derived cut points Flutemetamol [48] 20 AD patients, 20 MCI subjects Composite cortical binding correlation r = 0.905, slope = 0.99 100% concordance of individual subject visual scan categorization between ligands Florbetaben [57] 10 AD patients, 10 healthy control subjects Composite cortical binding correlation r = 0.97, P < .0001, slope = 0.71 100% concordance of individual subject visual scan categorization between ligands NAV4694 [53] 7 AD patients, 3 patients with frontotemporal dementia, 10 MCI subjects, 25 healthy control subjects Composite cortical binding correlation r = 0.99, P < .0001, slope = 0.95 100% concordance of individual subject visual scan categorization between ligands Abbreviations: PiB, Pittsburgh compound B; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
Scenario variable Variations considered Symptoms None Memory or cognitive complaint Clinical setting Nonmedical PCP Specialist Dementia specialist Clinical context Not applicable (nonmedical) Initial assessment Full evaluation, AD not suspected Full evaluation, AD suspected Evidence of deficit on examination Not applicable (nonmedical) None Yes MCI Mild—moderate dementia Severe dementia Family history of AD or apolipoprotein E ɛ4 positive Negative Positive AD genetic mutation carrier Negative Positive Not applicable Age <65 years >65 years Abbreviations: PCP, Primary Care Physician; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
- TABLE D1
Table of Relationships with Industry and Other Entities for Task Force Members and Outside Reviewers
Name Reported relationships with industry or other entities Bohnen, Nic • None Devous, Michael • Avid Pharmaceuticals • Lilly Healthcare • Bayer (now Piramal Pharmaceuticals) Donohoe, Kevin • None Drzezga, Alexander • Avid Radiopharmaceuticals/Lilly Healthcare • Bayer Healthcare • GE Healthcare • Siemens Healthcare Foster, Norman • Bristol-Meyers Squibb • GE Healthcare • Janssen AI • Center for Health Improvement Herholz, Karl • GE Healthcare • Elan • Avid Radiopharmaceuticals/Lilly Healthcare Herscovitch, Peter • None Johnson, Keith • Siemens • Avid Radiopharmaceuticals/Lilly Healthcare • Janssen AI • Bayer • Navidea Biopharmaceuticals • Piramal Healthcare Karlawish, Jason • Alzheimer’s Disease Cooperative Study (member) Minoshima, Satoshi • None Rabinovici, Gil • Avid Radiopharmaceuticals Rowe, Christopher • Bayer • GE Healthcare • AstraZeneca • Piramal Healthcare • Avid Radiopharmaceuticals/Lilly Healthcare • Navidea Biopharmaceuticals Villemagne, Victor • Bayer Wolk, David • Pfizer • GE Healthcare
Jump to section
- Article
- Abstract
- 1. INTRODUCTION
- 2. BACKGROUND
- 3. METHODS
- 4. DEFINITIONS
- 5. PET Aβ RADIOPHARMACEUTICALS
- 6. RESULTS OF RATINGS
- 7. DISCUSSION OF INDIVIDUAL INDICATIONS
- 8. LIMITATIONS OF AMYLOID PET IN CLINICAL EVALUATION
- 9. AMYLOID PET AND ANTICIPATED IMPACT ON PATIENT CARE
- 10. IMAGE QUALITY AND REPORTING
- 11. FURTHER RESEARCH QUESTIONS
- Acknowledgments
- Appendix A: Task Force Members and Literature Reviewers
- Appendix B: Indications Subcommittee
- Appendix C: Literature Subcommittee and Evidence Review
- Appendix D: Relationships with Industry and Management of Conflicts of Interest
- Appendix E: Public Commentary
- Footnotes
- REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics
- Evaluation of Neurodegenerative Disorders with Amyloid-{beta}, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls
- Clinical utility of plasma A{beta}42/40 ratio by LC-MS/MS in Alzheimers disease assessment
- New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimers disease risk assessment
- Amyloid Imaging-Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease--What Lasts Long Finally Becomes Good?
- First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease
- Brain Imaging Quality Assurance: How to Acquire the Best Brain Images Possible
- Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification
- 18F-FDG and Amyloid PET in Dementia
- Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients
- Clinical Use and Utility of Amyloid Imaging
- SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0
- Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology
- Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation
- Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
- Amyloid Imaging in Dementia: Contribution or Confusion?
- PET Approaches for Diagnosis of Dementia
- The Medical Imaging & Technology Alliance Conference on Research Endpoints Appropriate for Medicare Coverage of New PET Radiopharmaceuticals